Sharma, A., Subudhi, S., Blando, J., Scutti, J., Vence, L., Wargo, J., … Sharma, P. (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)

Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., … Sharma, P. (2018). Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI99760 (Original work published 2018)

Gao, J., Ward, J., Pettaway, C., Shi, L., Subudhi, S., Vence, L., … Sharma, P. (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308